Faron Pharmaceuticals Oy (LON:FARN) Shares Down 58.9% – Here’s Why

Faron Pharmaceuticals Oy (LON:FARN) traded down 58.9% during trading on Tuesday . The company traded as low as GBX 64.50 and last traded at GBX 67.80. 1,036,659 shares traded hands during trading, an increase of 2,241% from the average session volume of 44,276 shares. The stock had previously closed at GBX 165.

Faron Pharmaceuticals Oy Trading Down 59.4%

The stock has a market capitalization of £76.66 million, a price-to-earnings ratio of -2.48 and a beta of 0.36. The company has a current ratio of 1.45, a quick ratio of 1.09 and a debt-to-equity ratio of 922.55. The company has a fifty day moving average of GBX 175.74 and a two-hundred day moving average of GBX 187.64.

Insider Activity

In other Faron Pharmaceuticals Oy news, insider Jurriaan Dekkers sold 4,000 shares of the firm’s stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of GBX 182, for a total value of £7,280. Corporate insiders own 4.05% of the company’s stock.

Faron Pharmaceuticals Oy Company Profile

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.